Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.85 USD | -1.60% | -6.38% | +28.47% |
Apr. 23 | Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment | CI |
Apr. 10 | Silo Pharma Says It Exercised Option to License Alzheimer's Therapeutic From Columbia University | MT |
Financials (USD)
Sales 2024 * | 72K | Sales 2025 * | 72K | Capitalization | 5.26M |
---|---|---|---|---|---|
Net income 2024 * | -4M | Net income 2025 * | -8M | EV / Sales 2024 * | 73.1 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 73.1 x |
P/E ratio 2024 * |
-3.3
x | P/E ratio 2025 * |
-2.64
x | Employees | 3 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.01% |
1 day | -1.60% | ||
1 week | -6.38% | ||
Current month | -5.12% | ||
1 month | -3.14% | ||
3 months | +20.13% | ||
6 months | +38.06% | ||
Current year | +28.47% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 10-07-12 |
Daniel Ryweck
DFI | Director of Finance/CFO | 59 | 22-09-26 |
James Kuo
CTO | Chief Tech/Sci/R&D Officer | 58 | 22-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Weisblum
CEO | Chief Executive Officer | 54 | 10-07-12 |
Wayne Linsley
BRD | Director/Board Member | 67 | 20-01-15 |
Kevin Muñoz
BRD | Director/Board Member | 46 | 20-09-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 1.85 | -1.60% | 55,867 |
24-04-25 | 1.88 | +0.01% | 68,152 |
24-04-24 | 1.88 | +5.62% | 386,261 |
24-04-23 | 1.78 | -10.55% | 5,264,037 |
24-04-22 | 1.99 | +0.71% | 59,321 |
Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+28.47% | 5.26M | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-16.09% | 15.36B | |
-9.14% | 11.95B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
+5.24% | 8.71B |
- Stock Market
- Equities
- SILO Stock